Prosecution Insights
Prosecution Insights
13 pending office actions • 2 clients • 13 examiners • 8 art units • 0 of 13 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (23%) |
| §112 only | 2 (15%) |
| Double-patenting only | 4 (31%) |
| No statute on record | 4 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.3% | +34.5% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.2% |
| O'BRIEN, LEA S | 1 | 51.4% | +13.9% |
| LUNDE, GRACE HENRY | 1 | 65.4% | +35.9% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 59.6% | +67.3% |
| DRISCOLL, LORA E BARNHART | 1 | 31.6% | +20.1% |
| NOAKES, SUZANNE MARIE | 1 | 73.1% | +18.3% |
| DEBERRY, REGINA M | 1 | 49.8% | +30.6% |
| HAM, JIEUN | 1 | 60.0% | +53.3% |
| HOWARD, ZACHARY C | 1 | 63.9% | +38.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | MOSELEY II, NELSON B | — |
| 18338985 | METHODS FOR TREATMENT OF PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE | O'BRIEN, LEA S | — |
| 18324863 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | LUNDE, GRACE HENRY | — |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | CUNNINGCHEN, KATHLEEN MARY | — |
| 18319406 | ANTI-CD3 ANTIBODIES AND METHODS OF USE | DRISCOLL, LORA E BARNHART | — |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | NOAKES, SUZANNE MARIE | — |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | DEBERRY, REGINA M | — |
| Client (Assignee) | Pending OAs |
|---|---|
| GENENTECH, INC. | 8 |
| Roche | 5 |
| Art Unit | Apps |
|---|---|
| 1646 | 4 |
| 1641 | 2 |
| 1643 | 2 |
| 1642 | 1 |
| 3991 | 1 |
| 1656 | 1 |
| 1647 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | Genentech, Inc. | GUSTILO, ESTELLA M | 1646 | — | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | Genentech, Inc. | MOSELEY II, NELSON B | 1642 | — | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18338985 | METHODS FOR TREATMENT OF PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE | Hoffmann-La Roche, Inc. | O'BRIEN, LEA S | 1646 | DP | Non-Final OA | — | Pending | Jun 21, 2023 |
| 18324863 | PREVENTION OR MITIGATION OF T-CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS | Hoffmann-La Roche, Inc. | LUNDE, GRACE HENRY | 1641 | DP | Non-Final OA | — | Pending | May 26, 2023 |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Genentech, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18319406 | ANTI-CD3 ANTIBODIES AND METHODS OF USE | Genentech, Inc. | DRISCOLL, LORA E BARNHART | 3991 | Other | Non-Final OA | — | Pending | May 17, 2023 |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | Genentech, Inc. | NOAKES, SUZANNE MARIE | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | Hoffmann-La Roche, Inc. | DEBERRY, REGINA M | 1647 | DP | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18300169 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE | Hoffmann-La Roche, Inc. | HAM, JIEUN | 1643 | DP | Non-Final OA | — | Pending | Apr 13, 2023 |
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | Genentech, Inc. | HOWARD, ZACHARY C | 1674 | §103 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Hoffmann-La Roche, Inc. | CHATTIN, AMY MARIE | 1643 | Other | Non-Final OA | 26d | Pending | Dec 15, 2022 |
| 17783229 | ANTI-PD-L1 ANTIBODY FORMULATIONS | Genentech, Inc. | KIM, YUNSOO | 1641 | §103 | Final Rejection | — | Pending | Jun 07, 2022 |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | Genentech, Inc. | CHASE, CAROL ANN | 1646 | §103 | Final Rejection | 4d overdue | Pending | Sep 13, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial